Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on Jun 19, 2020 12:37pm

102 Views

Post# 31169953

RE:RE:RE:RE:Weekly Sales Update

I appreciate those numbers ... No matter what. I kind of hope they will eventually be closer to the reality. Thanks for sharing and thanks for your usual contribution. I also love Palinc's analysis and comments. I am a fan ! Lol

juniper88 wrote: They might not be that accurate but I believe they do point to a direction. For me, I would rather still see your posts.

SPCEO1 wrote: If the consensus here is for me to stop reporting them, that would be fine with me. Let me know what you all think.

Bucknelly21 wrote: I have to be honest the sales updates are a waste of your time, they are inaccurate numbers anyway on top of no one really caring about them. It's important to sell the drugs but making decisions based on an inaccurate reporting institution is pointless.